INTRODUCTION

Congenital complete atrioventricular block (CCAVB) is a rare, potentially lethal disease with an estimated incidence of 1 every 15,000 to 20,000 live births (1). A recent comparative study conducted in Finland demonstrated an increasing incidence from 1 to 25,000 to 1 to 11,000 during the last decades; possible explanations are the enhanced neonatal care and also that the better diagnostic methods allow more antenatal diagnosis, and moreover, the increasing number of mothers with connective tissue disease with successful delivery (2).

Nowadays, the diagnosis can be made in utero as early as between week 16 and 28 of gestation by fetal echocardiography. Aim of this review is to delineate the current knowledge on CCAVB presenting in children without structural heart disease: etiology, outcome, management and which are still the open problems.

Aetiology and outcome

There are two kinds of congenital heart block in structurally normal hearts: the first one is usually diagnosed in utero and is associated with the circulating maternal anti-Sjögren Syndrome A and anti-Sjögren Syndrome B antibodies (anti-SS-A/Ro and anti-SS-B/La ribonucleoproteins antibodies) (3-5). The other kind of CCAVB is detected later in the neonatal period or during infancy or childhood, and there is no clear association with maternal antibodies as in the first kind (4, 6).
The first demonstration of a correlation between maternal systemic lupus erythematosus (SLE) and CCAVB was described in 1977 (7); subsequently the association between the presence of maternal anti SS-A/Ro and anti SS-B/La and the development of a CCAVB was confirmed and tested in many series (6,8). The pathological changes have been strictly correlated to the presence of circulating Anti SS-A/Ro alone or in conjunction with Anti SS-B/La even in mothers without clinical manifestations of connective disease ( SLE, Sjögren’s syndrome, rheumatoid arthritis, mixed connective disease). The signature histologic pattern of autoimmune CCAVB is fibrous replacement of the conducting tissue and, sometimes, of the surrounding myocardium, but also a fibroelastosis replacement and widespread dystrophic calcifications in several areas have been reported (5, 9). The immuno-histology of hearts from fetuses/neonates with CCAVB demonstrated the presence of an exaggerated apoptosis and macrophage infiltrates resulting in a progressive scarring. The mechanisms by which maternal antibodies initiate and finally eventuate the fibrotic transformation are not clear (5); moreover, a recent report suggests that transplacental transfer of maternal cells during the pregnancy creates a state of microchimerism that may concur to the pathogenesis of cardiac injury in neonatal lupus. Associations between maternal HLA, not fetal HLA, and the CCAVB in the fetus, in presence of maternal immune disease, have been also described (10).

Third degree atrioventricular block seems irreversible, but the widespread use of fetal echocardiography also helps in diagnosis of first and second degree blocks in utero, opening a possibility of treatment. How, ever, it seems that incomplete AV block progresses to complete block post-natally despite the clearance of maternal antibodies from neonatal circulation (3). Recent reports suggest a direct role of maternal autoantibodies in inhibition of inward current calcium channels, and the presence of sinus bradycardia (SB) was identified, in an animal model, as a potential marker in detection and prevention of CCAVB (11) confirming clinical data correlating SB in infants born with mothers seropositive to anti SSA/Ro (12).

The immunologic basis of CCAVB can explain the development of dilated cardiomyopathy despite pacing; it seems that in up to 15% of cases a myocarditis/endocarditis occurs post-natally even after ten years (13, 14).

Echocardiography allows the in utero diagnosis and follow-up of CCAVB. The fetus may remain asymptomatic adjusting its stroke volume in order to compensate the bradycardia or may develop cardiac failure and intrauterine hydrops (15).

The mortality in infants with isolated CCAVB is estimated between 8 and 16% and between 4 and 8% in children and adults (1, 16). The mortality and morbidity of patients diagnosed outside the neonatal period is significantly lower than those with an in utero diagnosis (mortality of 5% vs 19% at a mean follow-up age of 22 years); early infancy seems the period of greatest risk of death (17).

Risk factors for worse outcome in CCAVB are fetal diagnosis, the presence of hydrops fetalis, delivery at 32 weeks gestation, and a ventricular rate <55 beats/min in early pregnancy (13, 18). Fetal hydrops was associated with a fetal and neonatal mortality between 83 and 100% in various reports and the coexistence of hydrops and endocardial fibroelastosis strongly predicts a worse prognosis (18).

Up to 50% of asymptomatic patients during childhood will complain of symptoms in adulthood and 10% will die prematurely; they could have the fatal event during their first Adams-Stokes episode (19, 20). A mean daytime heart rate < 50 beats/min has been reported as a risk factor for sincope and sudden death; moreover frequent episodes of junctional exit block, flat junctional response or tachyarrhythmias were present in patients who developed worse outcome (21).

In one report of 102 patients with CCAVB only 11% of neonatal and 12% of childhood patients had not required a pacemaker implant by the age of 20 years (13). Another negative prognostic sign is the presence of a prolonged QTc that has been reported in 7-22% of patients with CCAVB (20). In a recent report the overall morbidity of patients who survived is 17%; the presence of a dilated cardiomyopathy concurs to a worse outcome with a mortality rate of 75% (17).

**Management and therapeutic options**

Usually, the in utero diagnosis comes from the echocardiographic recognition of fetal bradycardia observing the difference in atrioventricular valve opening or ventricular activity in comparison to a higher atrial
rate (22).

The diagnosis in infancy and in childhood is not easy; in infancy a symptomatic bradycardia can manifest with poor growth and development, sometimes with sleep disorders such as nightmares and the need for frequent naps, or just simply with a sedentary attitude.

Several studies report in utero therapy with sympathomimetics, digitalis and steroids (4, 23, 24) in order to increase the heart rate, to reduce with digitalis both the heart failure and hydrops despite the AV block and to reduce the circulating maternal antibodies with steroids. Digoxin seems safe and represents a therapeutic option if the fetus presents with cardiac failure (23). Even if β-sympathomimetics can cause myocardial ischemia and pulmonary edema and sometimes the dosages needed to increase fetal heart rate are not tolerated by the mothers, the administration of maternal salbutamol can be an option in case of severe fetal bradycardia (24). Some positive effects have been registered in fetus with heart rate <55 beats/min with the maternal assumption of terbutaline every 4-6 hours (25, 26).

In a recent study the maternal assumption of corticosteroids was evaluated in presence of Anti SS-A/Ro, prior or after the 16th week of gestation: none of the neonates treated before the 16th week developed CCAVB compared to 25% of neonates whose mothers were not treated or treated after the 16th week (27).

Nowadays, pacemaker (PM) implantation has a pivotal role in management and therapy of CCAVB; even if eventually the patients will receive a PM, timing of implant depends strongly on symptoms and sometimes it is still controversial (28, 29).

In neonates with isolated CCAVB, the implant of a PM is recommended with a heart rate lower than 55 beats/min or if heart failure develops (30).

A recent study (16) identified the following indications for PM therapy: syncope, heart failure, left ventricular dilation, mitral valve regurgitation, unstable escape rhythm, inappropriate sinus tachycardia, a prolonged QT interval, presence of ventricular arrhythmias and a daytime bradycardia (<55bpm) in infants. In this study the PM therapy reduces both morbidity and mortality in children with CCAVB with and without cardiac malformation when compared to natural history data.

In addition, a prophylactic pacemaker treatment could be recommended in adolescents and young adults with CCAVB who are asymptomatic to prevent Adams-Stokes attacks and sudden death (31).

When the pediatric cardiologists decide the timing of PM implantation they need to evaluate also many technical elements. In the last two decades PM therapy in children has considerably improved mainly due to new generation generators, that are smaller, and to better leads, but in any case the morbidity and the necessity of reoperation and lead extraction still remain (16, 28, 30). Nowadays, the trend is towards a surgical approach in neonates and in preterms, implanting epicardial leads and especially steroid-eluting epicardial leads that demonstrated a longer longevity and a better threshold. The transvenous approach seems safe in children of 4-5 years of age with weight >10-20 kg; in infants and smaller children the diameter of innominate vein and superior vena cava is too small and there is the risk of occlusion (19, 30). Some centers are evaluating the implant of new smaller leads also in little children from both internal jugular and subclavian venous approach (32).

The PM generator is usually positioned in the abdominal wall with the epicardial lead surgical approach, and in a subpectoralis pocket if the transvenous approach is preferred. A typical problem with children is the out-growth of leads as the children grow up: the lead length should always be redundant in order to allow the out-growth of leads. Some authors suggest that the best positioning for the ventricular lead seems in the right ventricular outflow tract, because in children the heart grows in the long axis more than in short axis (19).

In children older than 3 years of age the double lead PM implant with a DDD mode is becoming more common (17). The DDD mode should be preferred in patients with sinus node dysfunction and some authors suggest the DDD mode in order to maintain the AV synchrony (33) although no definite evidence supports a preference for DDD mode versus single pacing lead (17, 28). Single pacing lead systems are well tolerated in children where VVIR mode responds adequately to their physiological needs and the incidence of pacemaker syndrome is low (17, 19, 34).

The follow-up of children with congenital complete heart block should include a complete clinical and in-
instrumental evaluation (ECG, Holter ECG monitoring and treadmill exercise test for heart rate and pauses evaluation, and echocardiogram in order to assess ventricular dimensions and function). As many authors suggest, the decision to implant a PM in an asymptomatic patient depends on the patient’s lifestyle, body size and on relative PM indications; when an adolescent reaches adult body size the benefit of the pacemaker in prevention of sudden death outweighs the risks of the implantation so the problem is to decide the proper timing of the implant (16, 17, 19, 35).

Address for correspondence:
Riccardo Cappato, MD
Arrhythmias and Electrophysiology Center
Policlinico San Donato, University of Milan, Italy
Via Morandi 30
20097 San Donato Milanese, (MI) - Italy
rcappato@libero.it

REFERENCES

1. Michealsson M, Engle M. Congenital complete heart block: An international study of the natural history. Cardiovasc Clin 1972; 4: 85-101.
2. Siren MK, Julkunen H, Kaaja R. The increased incidence of isolated congenital heart block in Finland. J Rheumatol 1998; 25: 1262-64.
3. Buyon JP, Hiebert R, Copel G, et al. Autoimmune-associated congenital heart block: Demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998; 31: 1658-66.
4. Eronen M, Heikkila P, Teramo K. Congenital complete heart block in the fetus: Hemodynamics features, antenatal treatment, and outcome in 6 cases. Pediatr Cardiol 2001; 22: 385-92.
5. Buyon JP, Clancy RM. Autoantibody-associated congenital heart block: TGFβ and the road to scar. Autoimmunity Reviews 2005; 4: 1-7.
6. Frohn-Mulder IM, Meiolf JF, Szatmari A, Stewart PA, Swaak TJ, Hess J. Clinical significance of maternal anti-Ro/SS-A antibodies in children with isolated heart block. J Am Coll Cardiol 1994; 23: 1677-81.
7. McCue CM, Mantakas ME, Tinglestad JB, Ruddy S. Congenital heart block in newborns of mothers with connective tissue disease. Circulation 1977; 56: 82-90.
8. Julkunen H, Kurki P, Kaaja R, et al. Isolated congenital heart block: Long-term outcome of mothers and characterization of the immune response to SS-A/SS-B and to SS-B/La. Arthritis Rheum 1993; 36: 1588-98.
9. Litsey SE, Noonan JA, O’Connor WN, Cottrill CM, Mitchell B. Maternal connective tissue disease and congenital heart block: Demonstration of immunoglobulin in cardiac tissue. N Eng J Med 1985; 312: 98-100.
10. Stevens A, Hermes H, Rutledge JC, Buyon JP, Nelson JL. Myocardial-tissue-specific phenotype of maternal microchimerism in neonatal lupus congenital heart block. Lancet 2003; 362: 1617-23.
11. Hu K, Qu Y, Yue Y, Boutjdir M. Functional basis of sinus bradycardia in congenital heart block. Circ Res 2004; 94: e32-38.
12. Brucato A, Cimaz R, Catelli L, Meroni P. Anti-Ro-associated sinus bradycardia in newborns. Circulation 2000; 102: E88-9.
13. Jaeggi ET, Hamilton RM, Silverman ED, Zamora SA, Hornberger LK. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution experience of 30 years. J Am Coll Cardiol 2002; 39: 130-7.
14. Moak JP, Barron KS, Hougen TJ, et al. Congenital heart block: Development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol 2001; 37: 238-42.
15. Veille JC, Covitz W. Fetal cardiovascular hemodynamics in the presence of complete atrioventricular block. Am J Obstet Gynecol 1994; 170: 1258-62.
16. Balmer C, Fasnacht M, Rahn M, Molinari L, Bausfeld U. Long-term follow-up in children with congenital complete atrioventricular block and the impact of pacemaker therapy. Europace 2002; 4: 345-9.
17. Eronen M. Long-term outcome of children with complete heart block diagnosed after the newborn period. Pediatr Cardiol 2001; 22: 133-7.
18. Groves AM, Allan LD, Rosenthal E. Outcome of isolated complete heart block diagnosed in utero. Heart 1996; 75: 190-4.
19. Friedman RA, Fenrich AL, Kertesz NJ. Congenital complete atrioventricular block. Pacing Clin Electrophysiol 2001; 24: 1681-8.
20. Michaelsson M, Jonzon A, Reisenfelt T. Isolated complete atrioventricular block in adult life: A prospective study. Circulation 1995; 92: 442-9.

21. Dewey RC, Capeless MA, Levy AM. Use of ambulatory electrographic monitoring to identify high risk patients with congenital complete heart block. N Engl J Med 1987; 316: 835-9.

22. Singh GK, Shumway JB, Amon E, et al. Role of fetal echocardiography in the management of isolated fetal heart block with ventricular rate < 55 bpm. Am J Perinatol 1998; 15: 661-8.

23. Anandakumar C, Biswas A, Chew SS, Chia D, Wong YC, Ratnam SS. Direct fetal therapy for hydrops secondary to congenital atrioventricular heart block. Obstet Gynecol 1996; 87: 835-7.

24. Groves AM, Allan LD, Rosenthal E. Therapeutic trial of sympathomimetics in three cases of complete heart block in the fetus. Circulation 1995; 92: 3394-6.

25. Chan AY, Silverman RK, Smith FC, et al. In utero treatment of fetal complete heart block with terbutaline. A case report. J Reprod Med 1999; 44: 385-7.

26. Heath DM, Bezold LI, Altman CA, et al. Oral terbutaline for the treatment of fetal complete atrioventricular block. J Am Soc Echocardiogr 1999; 12: 415.

27. Shinohara K, Miyagawa S, Fujita T, et al. Neonatal lupus erythematosus: Results of maternal corticosteroid therapy. Obstet Gynecol 1999; 93: 952-7.

28. Breur JM, Udink Ten Cate FE, Kapusta L, et al. Pacemaker therapy in isolated congenital complete atrioventricular block. Pacing Clin Electrophysiol 2002; 25: 1685-91.

29. Gregoratos G, Abrams J, Epstein A, et al. ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices. A Report of the American College of Cardiology/American Heart Association. Task Force on Practice Guidelines (ACC/AHA/NASPE Committee on Pacemaker Implantation). Circulation 2002; 106: 2145-61.

30. Gillette PC, Zeigler VL, Winslow AT, Kratz JM. Cardiac pacing in neonates, infants and preschool children. Pacing Clin Electrophysiol 1992; 15: 2046-9.

31. Eronen M, Siren MK, Ekblad H, Tikanoja T, Julkunen H Paavilainen T. Short- and long-term outcome of children with congenital complete heart block diagnosed in utero or as a newborn. Pediatrics 2000; 106: 86-91.

32. Molina JE, Dunnigan AC, Crosson JE. Implantation of transvenous pacemakers in infants and small children. Ann Thorac Surg 1995; 59: 689-94.

33. Bostan Ö, Celiker A, Karagöz T, Özer S, Özme S. Dual chamber cardiac pacing in children: Single chamber pacing dual chamber sensing cardiac pacemaker or dual chamber pacing and sensing cardiac pacemaker? Pedi atr International 2002; 44: 635-40.

34. Ragonese P, Guccione P, Drago F, et al. Efficacy and safety of ventricular rate responsive pacing in children with complete atrioventricular block. Pacing Clin Electrophysiol 1994; 17 (Pt I): 603-10.

35. Jonzon A. Congenital complete atrioventricular block. A pace in time saves lives (?) Europace 2002; 4: 343-4.